Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | KDM5A | P29375 | 2/20 | 0.38 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5551000 | 1.00 | TSHR (0.65) | TSHRALDH1A1DNM1TDP1THRB | |
| Bromide SCHEMBL8490443 | 1.00 | TSHR (0.65) | TSHRALDH1A1DNM1TDP1THRB | |
| SCHEMBL1883604 | 0.97 | TSHR (0.68) | TSHRALDH1A1DNM1TDP1THRB | |
| SCHEMBL1885691 | 0.97 | TSHR (0.68) | TSHRALDH1A1DNM1TDP1THRB | |
| SCHEMBL28337020 | 0.97 | TSHR (0.68) | TSHRALDH1A1DNM1TDP1THRB | |
| SCHEMBL28571943 | 0.92 | TSHR (0.60) | TSHRALDH1A1DNM1TDP1THRB | |
| SCHEMBL28573267 | 0.92 | TSHR (0.60) | TSHRALDH1A1DNM1TDP1THRB | |
| SCHEMBL6945510 | 0.92 | TSHR (0.60) | TSHRALDH1A1DNM1TDP1KCNH2 | |
| SCHEMBL21842845 | 0.92 | TSHR (0.60) | TSHRALDH1A1DNM1TDP1THRB | |
| SCHEMBL28820796 | 0.92 | TSHR (0.60) | TSHRALDH1A1DNM1TDP1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070190021-A1 | Poly(diallylamine)-based bile acid sequestrants | HOLMES-FARLEY STEPHEN R | 2007-08-16 | — | — | US | disclosed |
| US-7125547-B2 | Poly(diallylamine)-based bile acid sequestrants | GENZYME CORPORATION (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1014999-B1 | CATIONIC POLYMERS AS TOXIN-BINDING AGENTS | GENZYME CORP (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040151687-A1 | Poly(diallylamine)-based bile acid sequestrants | GENZYME CORPORATION | 2004-08-05 | — | — | US | disclosed |
| US-6726905-B1 | LOWERING SERUM PHOSPHATE | GENZYME CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-6692732-B2 | Administering cationic polymers to mammals to prevent poisons or antigens from microorganisms such as bacteria, viruses, fungi or parasites; deactivation | GENZYME CORPORATION | 2004-02-17 | — | — | US | disclosed |
| US-20040009145-A1 | IONIC POLYMERS AS TOXIN-BINDING AGENTS | GELTEX PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| US-6610283-B1 | Method for removing bile acids from a patient and certain polymers of use in the method. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer composition which includes a a | GENZYME CORPORATION | 2003-08-26 | — | — | US | disclosed |
| US-20020114774-A1 | Ionic polymers as toxin-binding agents | GELTEX PHARMACEUTICALS, INC. | 2002-08-22 | — | — | US | disclosed |
| US-6290947-B1 | IN ONE EMBODIMENT, THE POLYMER IS A COPOLYMER COMPRISING A MONOMER HAVING A PENDANT AMMONIUM GROUP AND A HYDROPHOBIC MONOMER. | GELTEX PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| US-6203785-B1 | ADMINISTERING CROSSLINKED CATIONIC POLYMER ANTICHOLESTEROL AGENTS | GELTEX PHARMACEUTICALS, INC. | 2001-03-20 | — | — | US | disclosed |
| US-6007803-A | ADMINISTERING TO MAMMAL A CATIONIC POLYMER TO INHIBIT PATHOGENIC TOXINS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| US-5969090-A | QUATERNIZED CROSSLINKED HYDROCARBON AMINE POLYMER | GELTEX PHARMACEUTICALS, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| US-5900475-A | MODIFIED POLYALLYLAMINE; ANTICHOLESTEROL AGENT | GELTEX PHARMACEUTICALS, INC. (US) | 1999-05-04 | — | — | US | disclosed |
| EP-0830390-A1 | HYDROPHOBIC HETEROATOM-CONTAINING SEQUESTRANT FOR CHOLESTEROL DEPLETION | GELTEX PHARMACEUTICALS, INC. (US) | 1998-03-25 | — | — | EP | disclosed |
| WO-1996039449-A1 | HYDROPHOBIC HETEROATOM-CONTAINING SEQUESTRANT FOR CHOLESTEROL DEPLETION | GELTEX PHARMACEUTICALS, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070190021-A1 | Poly(diallylamine)-based bile acid sequestrants | NR1H4, SLC10A2, SLC10A1 | TSHR 4075/4885ALDH1A1 2873/4885DNM1 3581/4885 |
| US-20040151687-A1 | Poly(diallylamine)-based bile acid sequestrants | NR1H4, SLC10A2, SLC10A1 | TSHR 4388/4885ALDH1A1 2717/4885DNM1 3469/4885 |
| US-20020114774-A1 | Ionic polymers as toxin-binding agents | PIGS, ANTXR2, MSN | TSHR 622/4885ALDH1A1 4693/4885DNM1 424/4885 |
| US-20040009145-A1 | IONIC POLYMERS AS TOXIN-BINDING AGENTS | PIGS, ANTXR2, MSN | TSHR 622/4885ALDH1A1 4693/4885DNM1 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.